H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on ALDX stock, giving a Buy rating on November 13.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matthew Caufield has given his Buy rating due to a combination of factors that highlight Aldeyra Therapeutics’ promising advancements and strategic positioning. The company is expanding its RASP modulator platform, particularly with ADX-248, which is being explored for various conditions including CNS neuroinflammatory diseases. This expansion is supported by preclinical progress in models of Parkinson’s and amyotrophic lateral sclerosis, which is seen as a positive development.
Additionally, the resolution of manufacturing inspection issues related to Reproxalap, without impacting its FDA assessment, strengthens confidence in its near-term potential. With the PDUFA date set for December 2025, there is optimism about FDA approval and a potential licensing agreement with AbbVie, which could lead to significant financial milestones. Reproxalap’s rapid efficacy in treating dry eye disease, along with its potential for broader applications, further supports the Buy rating.
In another report released on November 13, BTIG also maintained a Buy rating on the stock with a $9.00 price target.